coronary artery disease

DISCOVER INOCA Defines Vasomotor Disorders in Nonobstructive CAD

The DISCOVER INOCA registry provides a comprehensive definition of coronary vasomotor disorders in patients with ischemia and nonobstructive coronary arteries (INOCA).

ORBITA-CTO: CTO PCI Offers No Angina Relief Over Placebo

The ORBITA-CTO trial found no significant difference in angina symptom improvement between CTO PCI and a placebo procedure.

FFR or 3D-QCA Guided Revascularisation: The FAST III Trial

The FAST III trial, reported at ACC.26, investigated revascularisation guided by FFR versus 3D-QCA-based vessel-FFR.

Reverse-FALLS Protocol Reduces Pulmonary Congestion in CPE Patients

A prospective observational study demonstrated that the Reverse-FALLS protocol effectively reduced pulmonary congestion in patients with cardiogenic pulmonary edema.

IVUS Guidance Improves PCI Outcomes in Complex Bifurcation Lesions

Intravascular ultrasound (IVUS) guidance for percutaneous coronary intervention (PCI) in complex bifurcation lesions demonstrated superior outcomes compared to angiography guidance.

HOST-EXAM: Clopidogrel Monotherapy Non-Inferior to Aspirin at 10 Years

The HOST-EXAM trial's 10-year follow-up indicates clopidogrel monotherapy is non-inferior to aspirin monotherapy in stable CAD post-PCI with DES.

CHIP-BCIS3: LV Unloading Trial for High-Risk PCI

The CHIP-BCIS3 trial investigated percutaneous left ventricular unloading during high-risk coronary intervention, addressing a critical gap in managing complex PCI patients.

IVUS-Guided PCI Reduces MACE in Left Main Disease: OPTIMAL Trial

The OPTIMAL trial demonstrates IVUS-guided PCI significantly reduces major adverse cardiac events compared to angiography-guided PCI in unprotected left main coronary artery disease.

ALL-RISE: Angiography-Derived Physiology Non-Inferior to Pressure Wire for PCI

The ALL-RISE trial demonstrates non-inferiority of angiography-derived coronary physiology compared to invasive pressure wire guidance for PCI outcomes.

PCSK9 Inhibitors Move Upstream: Evolocumab Tested in Diabetes Without Known Atherosclerosis

VESALIUS-CV tests evolocumab in diabetic patients without established atherosclerosis, while new trials probe plaque biology and lipid pathways beyond LDL.